374 related articles for article (PubMed ID: 24531549)
1. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.
Politis M; Wu K; Loane C; Brooks DJ; Kiferle L; Turkheimer FE; Bain P; Molloy S; Piccini P
J Clin Invest; 2014 Mar; 124(3):1340-9. PubMed ID: 24531549
[TBL] [Abstract][Full Text] [Related]
2. Molecular imaging of levodopa-induced dyskinesias.
Niccolini F; Rocchi L; Politis M
Cell Mol Life Sci; 2015 Jun; 72(11):2107-17. PubMed ID: 25681866
[TBL] [Abstract][Full Text] [Related]
3. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
[TBL] [Abstract][Full Text] [Related]
4. The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study.
Smith R; Wu K; Hart T; Loane C; Brooks DJ; Björklund A; Odin P; Piccini P; Politis M
Neurobiol Aging; 2015 Apr; 36(4):1736-1742. PubMed ID: 25649022
[TBL] [Abstract][Full Text] [Related]
5. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
[TBL] [Abstract][Full Text] [Related]
6. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
[TBL] [Abstract][Full Text] [Related]
7. PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.
Pagano G; Yousaf T; Politis M
Curr Neurol Neurosci Rep; 2017 Oct; 17(11):90. PubMed ID: 28975571
[TBL] [Abstract][Full Text] [Related]
8. Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
Shin E; Garcia J; Winkler C; Björklund A; Carta M
Neurobiol Dis; 2012 Sep; 47(3):393-406. PubMed ID: 22579773
[TBL] [Abstract][Full Text] [Related]
9. The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies.
Pagano G; Niccolini F; Politis M
J Neural Transm (Vienna); 2018 Aug; 125(8):1217-1223. PubMed ID: 29264660
[TBL] [Abstract][Full Text] [Related]
10. Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
Nahimi A; Høltzermann M; Landau AM; Simonsen M; Jakobsen S; Alstrup AK; Vang K; Møller A; Wegener G; Gjedde A; Doudet DJ
J Neurochem; 2012 Mar; 120(5):806-17. PubMed ID: 22117574
[TBL] [Abstract][Full Text] [Related]
11. Chronic exposure to dopamine agonists affects the integrity of striatal D
Politis M; Wilson H; Wu K; Brooks DJ; Piccini P
Neuroimage Clin; 2017; 16():455-460. PubMed ID: 28879087
[TBL] [Abstract][Full Text] [Related]
12. 5-HT
Al-Kassmy J; Sun C; Huot P
Neurodegener Dis Manag; 2023 Apr; 13(2):101-112. PubMed ID: 37140165
[TBL] [Abstract][Full Text] [Related]
13. Dyskinesias in Parkinson's disease: views from positron emission tomography studies.
Niccolini F; Loane C; Politis M
Eur J Neurol; 2014 May; 21(5):694-9, e39-43. PubMed ID: 24471508
[TBL] [Abstract][Full Text] [Related]
14. Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias.
Roussakis AA; Politis M; Towey D; Piccini P
Neurology; 2016 Mar; 86(12):1152-8. PubMed ID: 26920358
[TBL] [Abstract][Full Text] [Related]
15. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
Kish SJ; Tong J; Hornykiewicz O; Rajput A; Chang LJ; Guttman M; Furukawa Y
Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909
[TBL] [Abstract][Full Text] [Related]
16. Buspirone in levodopa-induced dyskinesias.
Bonifati V; Fabrizio E; Cipriani R; Vanacore N; Meco G
Clin Neuropharmacol; 1994 Feb; 17(1):73-82. PubMed ID: 8149361
[TBL] [Abstract][Full Text] [Related]
17. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
[TBL] [Abstract][Full Text] [Related]
18. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease.
Ramlackhansingh AF; Bose SK; Ahmed I; Turkheimer FE; Pavese N; Brooks DJ
Neurology; 2011 May; 76(21):1811-6. PubMed ID: 21606452
[TBL] [Abstract][Full Text] [Related]
19. Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
Azkona G; Sagarduy A; Aristieta A; Vazquez N; Zubillaga V; Ruíz-Ortega JA; Pérez-Navarro E; Ugedo L; Sánchez-Pernaute R
Neuropharmacology; 2014 Apr; 79():726-37. PubMed ID: 24333147
[TBL] [Abstract][Full Text] [Related]
20. Altered brain structural topological properties in Parkinson's disease with levodopa-induced dyskinesias.
Wang L; Wang M; Si Q; Yuan Y; Ma K; Gan C; Zhang K
Parkinsonism Relat Disord; 2019 Oct; 67():36-41. PubMed ID: 31621605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
